Hot Deals:
5 star business 505.00 (1.00 %) a v thomas 12,800.00 (-1.54 %) aether industries 642.00 amol minechem 620.00 (1.64 %) anglo french 720.00 (-5.26 %) apl metals 44.00 (-2.22 %) aricent 595.00 (-0.83 %) arohan 197.00 (-3.90 %) assam carbon 243.00 (-2.80 %) atlas copco 5,050.00 (3.06 %) auckland 135.00 (-3.57 %) axles 135.00 (-3.57 %) b9 bira 830.00 (-1.19 %) balmer lawrie van leer 300.00 bharat hotels 162.00 (1.25 %) bikaji foods 360.00 (5.88 %) boat 1,030.00 (-5.50 %) c & s electric 400.00 capgemini 12,000.00 (-4.00 %) care health 145.00 (-3.33 %) carrier aircon 261.00 (-3.33 %) cial 185.00 (-0.54 %) csfbl 300.00 (-0.99 %) csk 178.00 (1.71 %) dalmia bharat refractories 95.00 (-4.04 %) delhivery 504.00 (-1.75 %) east india pharmaceutical 43.00 (2.38 %) eaton fluid 281.00 (0.36 %) electronica plastic 4,300.00 (2.38 %) elgi ultra 400.00 elofic 1,909.00 (0.47 %) epiroc 1,224.00 (-2.08 %) esl steel 46.00 (-2.13 %) fincare 69.50 (-0.71 %) fino paytech 165.00 (-2.94 %) frick india 4,140.00 (-3.72 %) gkn drive 1,150.00 (-0.95 %) godavari biorefineries 71.00 (1.43 %) hdbfsl 656.00 (-2.09 %) hdfc ergo 363.80 hdfc securities 13,700.00 (-2.14 %) hella india 158.00 (1.94 %) hero fincorp 800.00 (-5.88 %) hicks 2,100.00 (-2.55 %) hira ferro 140.00 (-6.67 %) honeywell electrical 4,240.00 (-0.24 %) icex 5.60 (-6.67 %) incred financial 100.00 india carbon 1,300.00 (1.56 %) india exposition mart 132.00 (-2.22 %) indian potash limited 1,405.00 (0.36 %) indofil industries 710.00 (-3.40 %) infinite computer 700.00 inkel 12.95 (-0.38 %) ixigo 111.00 (-5.13 %) jana sfbl 75.00 kial 120.00 (-2.44 %) klm axiva 10.00 kurlon enterprise 640.00 (-3.03 %) kurlon limited 450.00 (-2.17 %) lava 155.00 (-3.13 %) manipal hfsl 72.50 (0.69 %) manjushree technopack 1,150.00 (-3.36 %) martin and harris 2,070.00 (-5.91 %) merino 2,900.00 (-4.92 %) minosha 320.00 (-1.54 %) mitsubishi heavy industries 355.00 (1.43 %) mkcl 415.00 (1.22 %) mobikwik 555.00 (-7.50 %) mohan meakin 1,250.00 (-3.85 %) mohfl 11.50 (-4.17 %) msei 1.19 (-0.83 %) msil 54.00 (-1.82 %) ncdex 275.00 ncl buildtek 245.00 (-2.00 %) ncl holdings 48.00 (-4.00 %) nse 3,411.00 (-0.26 %) orbis financial 72.00 (2.86 %) oswal minerals 42.50 (1.19 %) otis 4,000.00 (-2.44 %) oyo rooms 100.00 (-9.91 %) panasonic appliances 306.00 (0.33 %) panasonic avc 29.10 (0.34 %) paymate india 630.00 (-10.00 %) pharm easy 54.00 (-1.82 %) philips domestic 565.00 (-4.24 %) philips india 1,150.00 (-2.21 %) pnb metlife 70.00 proyuga adtech 25.00 ramaraju surgical 540.00 (-4.42 %) reliance general insurance 340.00 resins plastics 406.00 (0.25 %) ring plus 350.00 (-3.05 %) rrl 3,000.00 (-1.64 %) sabmiller 400.00 (-1.23 %) satya micro 200.00 scottish assam 654.00 (0.62 %) shriram life 251.00 (0.40 %) signify 1,126.00 (0.09 %) smile microfin 80.00 (-2.44 %) sri vishnu shankar 640.00 (-1.54 %) sterlite power 900.00 (-1.10 %) studds 1,310.00 (-2.96 %) t stanes 675.00 tata tech 4,910.00 (0.20 %) tmbl 525.00 (1.94 %) trl krosaki 1,390.00 (-0.71 %) utkarsh coreinvest 166.00 (0.61 %) vikram solar 51.00 (2.00 %) xerox 261.00 (0.38 %)
×

martin and harris laboratories Limited

2,070.00
-5.91 %
Scrip Name
MARTIN AND HARRIS
ISIN No.
INE03VV01015
PAN No.
AABCM0832A
Face Value
10
No. of Outstanding Shares
3,996,040
Market Capitalization
827.18 Crore

MARTIN AND HARRIS LABORATORIES LIMITED UNLISTED SHARE


ABOUT MARTIN AND HARRIS LABORATORIES LIMITED


MARTIN AND HARRIS LABORATORIES LIMITED was first established in 1996 and is based in Gurgaon, Haryana. The company is a part of Apeejay Group, which is India’s oldest and largest Conglomerates. Apeejay Group is a leading Industrial & Investment house with businesses in Automotive, Chemicals & Plastics, Distribution, Logistics & Retail, Pharmaceuticals & life sciences, real estate, and international trading and a nascent presence in IT, merchant banking & financial services and publishing.


Martin and Harris Laboratories Limited is primarily engaged in the business of manufacturing pharmaceuticals, medicinal chemicals & botanical products. The company intensively focuses on drugs used for Hyper Tension, High blood pressure, and heart attack. Apart from its primary business, the company also undertakes fund management through investment in different avenues like mutual funds, equity, etc.


Martin and Harris Laboratories Limited has two units located at Roorkee, Uttarakhand, and Una in Himachal Pradesh. The company is continuously striving to expand its manufacturing facilities and meet global standards.


The company was awarded ‘Best Pharma Excellence awards’ in 2018 by ASSOCHAM India.



INCORPORATION DETAILS


CIN

U24239HR1993PLC033630

Registration Date

22 July 1993

Category/Sub-category of the Company

Company Limited by Shares

Address of the Registered office and contact details

NH-8, Delhi Jaipur Highway,

Village, Pachgaon (Fazalwas),

District Gurgaon, Haryana

Name, Address and Contact Details of

Registrar and Transfer Agent, if any

NA

PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

Name and Description of main products/services

NIC Code of the product/service

% to total turnover of the Company

Manufacture of Pharmaceutical, Medicinal Chemical & Botanical Products

210

52.03%

Fund management activities

663

47.97%

 

BOARD OF DIRECTORS

MR. S. L. LAAD

MR. G. K. NIGAM

MR. AJAY GROVER

MR. H. S. THAKUR


PARTICULARS OF SUBSIDIARY COMPANIES

Name of the Company

% of shares held

Delite Infrastructure Private limited

100.00%

 

 

MARTIN AND HARRIS LABORATORIES LIMITED UNLISTED SHARE DETAILS


Total Available Shares:

39,96,040

Face Value:

Rs. 10 Per Equity Share

ISIN:

INE03VV01015

PAN No.:

AABCM0832A

Lot Size:

50 Shares

Last Traded Price:

Rs. 1800

Market Cap:

Rs. 719.29 Crore


SHAREHOLDING PATTERN

(As on 31-03-2020)

S. No.

Shareholders’ Name

Number of shares

% of total Shares of the company

1

Promoters Shareholding

140

0.004%

2

Public Shareholding

39,95,900

99.996%

 

Total

39,96,040

100.00%


INDUSTRY OUTLOOK

 

Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of the global demand for various vaccines, 40% of generic demands in the USA, and 25% of all the medicines in the United Kingdom. Excellent Research & Development, low cost of labor, availability of management and technical personnel, and local equipment’s availability has helped India to manufacture pharma products at a very low cost.


The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID 19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.


Export of Pharmaceuticals products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat the covid patients in the initial stage of the covid-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.


After the onset of COVID 19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.

 

KEY FINANCIALS OF MARTIN AND HARRIS LABORATORIES LIMITED(In Rs. Lakhs)

 

Particulars

2020

2019

2018

2017

Revenue from Operations

26,729.47

24,723.47

16,655.48

13,448.93

EBITDA

6,385.87

5,108.93

7,073.97

4,032.14

EBITDA margin

23.89%

20.66%

42.47%

29.98%

Finance Cost

25.04

7.36

19.26

142.89

Depreciation

156.22

164.73

133.49

137.24

Other Income

2,937.53

4,267.03

1,082.88

260.26

Profit Before Tax

9,142.15

9,203.87

8,004.11

4,012.27

Total Tax

2,220.50

1,959.86

2,066.32

1,118.53

Profit After Tax (PAT)

6,921.65

7,244.01

5,937.79

2,893.74

EPS

173.21

181.28

148.59

72.42

 

BALANCE SHEET OF MARTIN AND HARRIS LABORATORIES LIMITED(In Rs. Lakhs)

Particulars

2020

2019

ASSETS



NON CURRENT ASSETS



Tangible assets

5,530.50

4693.41

Investments

25,736.37

4178.87

TOTAL NON CURRENT ASSETS

31,266.87

8,872.28

CURRENT ASSETS



Inventories

2,058.24

1,021.08

Trade Receivables

1,844.65

563.40

Cash and Cash Equivalents

77.85

59.25

Short-Term Loans and Advances

1,385.53

16,762.58

Other Current Assets

18.73

17.83

TOTAL CURRENT ASSETS

5,384.99

18,424.13

TOTAL ASSETS

36,651.86

27,296.41

EQUITY AND LIABILITIES



EQUITY



Share capital

399.60

399.60

Reserves and Surplus

32,254.02

25,443.64

TOTAL EQUITY

32,653.63

25,843.25

LIABILITIES



NON CURRENT LIABILITIES



Long Term Borrowings

460.61

456.62

Deferred Tax Liabilities (Net)

61.39

66.73

TOTAL NON CURRENT LIABILITIES

522.00

523.35

CURRENT LIABILITIES



Short Term Borrowings

920.75

1.08

Trade Payables

1,773.14

499.01

Other Current Liabilities

1.95

0.84

Short-Term Provisions

780.41

428.89

TOTAL CURRENT LIABILITIES

3,476.24

929.81

TOTAL LIABILITIES

3,998.23

1,453.16

TOTAL EQUITY AND LIABILITIES

36,651.86

27,296.41

 

DIVIDEND HISTORY

Particulars

2020

2019

2018

Dividend (final + interim) (In Rs.)

2.20

2.20

1.8

 

PERFORMANCE OF THE COMPANY

Revenue from Operations of the company increased by 8% from Rs. 24,723.47 lakhs in FY 2019 to Rs. 26,729.47 lakhs in FY 2020.


EBITDA of the company increased by 25% from Rs. 5,108.93 lakhs in FY 2019 to Rs. 6,385.87 lakhs in FY 2020. EBITDA margin of the company increased from 20.66% in FY 2019 to 23.89% in FY 2020.


Profit after tax of the company decreased by 4% from Rs. 7,244.01 lakhs in FY 2019 to Rs. 6,921.65 lakhs in FY 2020.


The current ratio of the company as of 31st March 2020 was 1.54.


The debt to equity ratio of the company as of 31st March 2020 was 0.04. The company is almost a debt-free company.


Return on Equity for the company for FY 2020 was 21.19%.


Book value per equity share of the company as of 31st march 2020 was Rs. 817.14.


Martin and Harris Laboratories Limited has consistently given dividends for the past three years. For FY 2020, the company has given a dividend of Rs. 2.20.


Powered by Froala Editor

Wealth Wisdom - WWIPL
Support Megha Support Neha Support Pallavi